Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic Non-small Cell Lung Cancer (NSCLC) Condition: Anaplastic lymphoma kinase (ALK)-positive |
Dose: Tablet – 600 mg Frequency: twice daily by mouth Note: Take with food; continue until disease progression or unacceptable toxicity |
|
Indication: Adjuvant treatment of Non-small Cell Lung Cancer (NSCLC) Age: Adults Condition: Anaplastic lymphoma kinase (ALK)-positive following tumor resection (tumors greater than or equal to 4 cm or node positive) |
Dose: Tablet – 600 mg Frequency: twice daily by mouth Duration: 2 years Note: Take with food; continue for a total of 2 years or until disease progression or unacceptable toxicity |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: No approved pediatric dosage available Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild-to-moderate renal impairment |
Dose: No dose adjustment required Note: Renal impairment |
|
Condition: Severe renal impairment (Creatinine Clearance less than 30 mL/min) or End-Stage Renal Disease |
Dose: Not studied Note: Renal impairment |
Administration
- Take with food
- Swallow capsules whole
Side Effect
- Anemia (56%)
- Increased AST (51%)
- Increased alkaline phosphatase (47%)
- Increased CPK (43%)
- Fatigue (26-41%)
- Hyperbilirubinemia (39%)
- Hyperglycemia (36%)
- Increased ALT (34%)
- Constipation (34%)
- Hypocalcemia (32%)
- Edema (22-30%)
- Hypokalemia (29%)
- Myalgia (23-29%)
- Increased creatinine (28%)
- Lymphopenia (22%)
- Hypophosphatemia (21%)
- Hyponatremia (20%)
- Cough (19%)
- Rash (15-18%)
- Nausea (14-18%)
- Headache (17%)
- Diarrhea (12-16%)
- Dyspnea (16%)
- Back pain (12%)
- Vomiting (7-12%)
- Bradycardia (11%)
- Increased weight (11%)
- Vision disorder (10%)
- Increased ALT (4.8%)
- Increased CPK (4.6%)
- Lymphopenia (4.6%)
- Vision disorders (4.6%)
- Hypokalemia (4%)
- Renal impairment (3.9%)
- Dyspnea (3.6%)
- Increased AST (3.6%)
- Dysgeusia (3.3%)
- Hypophosphatemia (2.8%)
- Hyperbilirubinemia (2.4%)
- Hyperglycemia (2%)
- Hyponatremia (2%)
- Anemia (2%)
- Fatigue (1.2%)
- Myalgia (1.2%)
- Diarrhea (1.2%)
- Increased alkaline phosphatase (1.2%)
- Edema (0.7-0.8%)
- Headache (0.8%)
- Rash (0.4-0.7%)
- Dysgeusia (0.7%)
- Nausea (0.7%)
- Vomiting (0.4%)
- Increased weight (0.4%)
- Hypocalcemia (0.4%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) transporters substrates (e.g. digoxin, dabigatran, methotrexate)
|
May increase plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.